Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dick C Chan

Showing results (61-70 of 176) with videos related to

Pageof 18
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|January 18, 2006
Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kineticsDick C Chan, Gerald F Watts, Minh N Nguyen, et al.
The American Journal of Clinical Nutrition|July 11, 2006
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesityDick C Chan, Gerald F Watts, Minh N Nguyen, et al.
The Journal of Clinical Endocrinology and Metabolism|November 15, 2007
Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolismDick C Chan, Minh N Nguyen, Gerald F Watts, et al.
Pharmaceuticals (Basel, Switzerland)|November 24, 2022
Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical ExperienceClaudia Stefanutti, Dick C Chan, Serafina Di Giacomo, et al.
Atherosclerosis|August 11, 2016
Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resinGerald F Watts, Jing Pang, Dick C Chan, et al.
European Journal of Clinical Investigation|March 16, 2022
Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments?Qidi Ying, Annalisa Ronca, Dick C Chan, et al.
Clinical Science (London, England : 1979)|May 22, 2009
Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndromeTheodore W K Ng, Dick C Chan, P Hugh R Barrett, et al.
Diabetes Research and Clinical Practice|July 4, 2009
Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetesEsther M M Ooi, Theodore W K Ng, Dick C Chan, et al.
Clinical Science (London, England : 1979)|April 11, 2008
Apolipoprotein C-III: understanding an emerging cardiovascular risk factorEsther M M Ooi, P Hugh R Barrett, Dick C Chan, et al.
Circulation|July 5, 2017
Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism"Gerald F Watts, Dick C Chan, Ransi Somaratne, et al.
Pageof 18

Showing results (61-70 of 176) with videos related to

Sort By:
Pageof 18
Arteriosclerosis, Thrombosis, and Vascular Biology|January 18, 2006
Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kineticsDick C Chan, Gerald F Watts, Minh N Nguyen, et al.
The American Journal of Clinical Nutrition|July 11, 2006
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesityDick C Chan, Gerald F Watts, Minh N Nguyen, et al.
The Journal of Clinical Endocrinology and Metabolism|November 15, 2007
Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolismDick C Chan, Minh N Nguyen, Gerald F Watts, et al.
Pharmaceuticals (Basel, Switzerland)|November 24, 2022
Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical ExperienceClaudia Stefanutti, Dick C Chan, Serafina Di Giacomo, et al.
Atherosclerosis|August 11, 2016
Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resinGerald F Watts, Jing Pang, Dick C Chan, et al.
European Journal of Clinical Investigation|March 16, 2022
Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments?Qidi Ying, Annalisa Ronca, Dick C Chan, et al.
Clinical Science (London, England : 1979)|May 22, 2009
Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndromeTheodore W K Ng, Dick C Chan, P Hugh R Barrett, et al.
Diabetes Research and Clinical Practice|July 4, 2009
Plasma markers of cholesterol homeostasis in metabolic syndrome subjects with or without type-2 diabetesEsther M M Ooi, Theodore W K Ng, Dick C Chan, et al.
Clinical Science (London, England : 1979)|April 11, 2008
Apolipoprotein C-III: understanding an emerging cardiovascular risk factorEsther M M Ooi, P Hugh R Barrett, Dick C Chan, et al.
Circulation|July 5, 2017
Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism"Gerald F Watts, Dick C Chan, Ransi Somaratne, et al.
Pageof 18